Literature DB >> 18172815

Rational design of nasal vaccines.

Bram Slütter1, Niels Hagenaars, Wim Jiskoot.   

Abstract

Nasal vaccination is a promising alternative to classical parental vaccination, as it is non-invasive and, in principle, capable of eliciting strong systemic and local immune responses. However, the protective efficacy of nasally administered antigens is often impaired because of delivery problems: free antigens are readily cleared from the nasal cavity, poorly absorbed by nasal epithelial cells and generally have low intrinsic immunogenicity. In this review paper, we describe the main physiological hurdles to nasal vaccine delivery, survey the progress made in technological approaches to overcome these hurdles and discuss emerging opportunities for improving nasal vaccines. According to current insights, encapsulation of the antigen into bioadhesive (nano)particles is a promising approach towards successful nasal vaccine delivery. These antigen-loaded particles can be tailor made by supplying them with targeting ligands, adjuvants or endosomal escape mediators to form the desired vaccine that provides long-lasting protective immunity.

Mesh:

Substances:

Year:  2008        PMID: 18172815     DOI: 10.1080/10611860701637966

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  25 in total

1.  Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Authors:  Karen Nieto; Christiane Stahl-Hennig; Barbara Leuchs; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen.

Authors:  Alexandra Mant; Fay Chinnery; Tim Elliott; Anthony P Williams
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

3.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 4.  Polymeric nanoparticle drug delivery technologies for oral delivery applications.

Authors:  Eric M Pridgen; Frank Alexis; Omid C Farokhzad
Journal:  Expert Opin Drug Deliv       Date:  2015-03-26       Impact factor: 6.648

5.  Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array.

Authors:  Zhi Ding; Suzanne M Bal; Stefan Romeijn; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-03-17       Impact factor: 4.200

6.  Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.

Authors:  Yuhong Jiang; Man Li; Zhirong Zhang; Tao Gong; Xun Sun
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

7.  NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.

Authors:  Lindsay J Hall; Simon Clare; Gordon Dougan
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

8.  Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines.

Authors:  Paul E Makidon; Shraddha S Nigavekar; Anna U Bielinska; Nicholas Mank; Abhishek M Shetty; Julie Suman; Jessica Knowlton; Andrzej Myc; Trent Rook; James R Baker
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

9.  Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

Authors:  David J M Lewis; Zhiming Huo; Susan Barnett; Ingrid Kromann; Rafaela Giemza; Eva Galiza; Maria Woodrow; Birgit Thierry-Carstensen; Peter Andersen; Deborah Novicki; Giuseppe Del Giudice; Rino Rappuoli
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

10.  Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Authors:  Niels Hagenaars; Enrico Mastrobattista; Rolf J Verheul; Imke Mooren; Harrie L Glansbeek; Jacco G M Heldens; Han van den Bosch; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.